



# SUSTAINABLE

# SUPPORTING

# ACCESS



**Sanofi Genzyme's Humanitarian Program** is the first humanitarian initiative and longest-running program of its kind for people with lysosomal storage disorders. Since it was introduced in 1991, the program has been focused on providing access to free treatments for patients that meet the program's criteria, who otherwise would not have access to such treatments. The Humanitarian Program is also a key component of Sanofi Genzyme's broader support for patient diagnosis, treatment monitoring, patient advocacy and physician education for lysosomal storage disorders.

**DID YOU KNOW?**

**3,300+**  
people in  
**100+ countries**

have received access to free therapy through the program since it began in 1991.

**1,000+**  
people in  
**70+ countries**

are currently receiving access to free therapy through the program today.

**350+**  
people  
in our program

today have received access to free therapy for over 10 years.

**150+**  
new patients

receive access to free therapy through this program each year.

## OUR COMMITMENT FOR 30 YEARS



Our Humanitarian Program began in 1991 and was established when our first treatment for Gaucher disease type 1 was approved by the U.S. FDA. Since then, **it has evolved and expanded to support five different lysosomal storage disorder communities across six continents.**



## A FOCUSED APPROACH

Our global team partners with local Sanofi Genzyme affiliates, patients and physicians to **understand the needs of the communities we serve.**

## A BRIDGE TO SUSTAINABLE CARE



Our program is based on the needs of the patients we serve. **It is a resource to support patients when treatment access is limited** and where this may be needed for several months or even for a decade or more.

**We believe that our responsibility does not end with developing effective therapies. We are also devoted to ensuring sustainable access to approved treatments for lysosomal storage disorders in patients with demonstrated need who meet the program's criteria, regardless of their ability to pay. Providing humanitarian support to the rare disease community is a vital element of our mission to improve patients' lives. It's in our DNA.**



For healthcare providers, many times our **Humanitarian Program serves as a physician's first experience in treating a lysosomal storage disorder patient.** Outside of the Humanitarian Program, Sanofi Genzyme helps support training and education for patient identification, understanding of treatment expectations and monitoring.



For governments, Sanofi Genzyme **collaborates with local officials to help establish sustainable healthcare systems** to care for the needs of patients with lysosomal storage disorders.



For the patient community, Sanofi Genzyme works closely with patient organizations to **help raise awareness of the unique challenges** having a lysosomal storage disorder brings and address the unmet needs of this population.